Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKUCNSX:BUXNYSE:CRLTSE:EDT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKUAkumin$0.18$0.12▼$1.90$26.32M-0.721.38 million shs8.54 million shsBUXBiomark Diagnostics$0.00$0.00▼$0.00N/AN/AN/A11,500 shsCRLCharles River Laboratories International$151.17+1.1%$129.61$91.86▼$254.15$7.42B1.481.00 million shs823,517 shsEDTSpectral MedicalC$0.87-1.1%C$0.82C$0.46▼C$0.89C$244.69M0.9661,126 shs6,500 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKUAkumin0.00%0.00%0.00%0.00%0.00%BUXBiomark Diagnostics0.00%0.00%0.00%0.00%0.00%CRLCharles River Laboratories International+1.11%+2.48%+7.21%-14.61%-27.83%EDTSpectral Medical-1.14%+6.10%+2.35%+31.82%+77.55%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKUAkuminN/AN/AN/AN/AN/AN/AN/AN/ABUXBiomark DiagnosticsN/AN/AN/AN/AN/AN/AN/AN/ACRLCharles River Laboratories International4.7195 of 5 stars3.15.00.04.72.42.51.9EDTSpectral MedicalN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKUAkumin 0.00N/AN/AN/ABUXBiomark Diagnostics 0.00N/AN/AN/ACRLCharles River Laboratories International 2.18Hold$171.8513.68% UpsideEDTSpectral Medical 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest BUX, CRL, EDT, and AKU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/23/2025CRLCharles River Laboratories InternationalRedburn AtlanticSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$188.00 ➝ $182.005/14/2025CRLCharles River Laboratories InternationalCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy5/14/2025CRLCharles River Laboratories InternationalTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$179.005/8/2025CRLCharles River Laboratories InternationalBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$145.00 ➝ $155.005/8/2025CRLCharles River Laboratories InternationalRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$118.00 ➝ $140.005/8/2025CRLCharles River Laboratories InternationalEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeIn-Line ➝ Outperform$170.004/10/2025CRLCharles River Laboratories InternationalBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$160.00 ➝ $145.004/9/2025CRLCharles River Laboratories InternationalMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$175.00 ➝ $155.003/21/2025CRLCharles River Laboratories InternationalThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$190.00 ➝ $170.00(Data available from 6/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKUAkumin$749.63M0.00N/AN/A$1.24 per share0.00BUXBiomark DiagnosticsN/AN/AN/AN/AN/AN/ACRLCharles River Laboratories International$4.02B1.85$20.21 per share7.48$67.80 per share2.23EDTSpectral MedicalC$1.90M128.78C$0.01 per share82.50C($0.08) per share-10.88Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKUAkumin-$156.76M-$2.52N/AN/AN/A-30.56%-167.86%-7.81%N/ABUXBiomark DiagnosticsN/AN/A0.00N/AN/AN/AN/AN/AN/ACRLCharles River Laboratories International$474.62M-$0.651,007.7713.744.540.52%14.69%6.79%8/6/2025 (Estimated)EDTSpectral Medical-C$18.68M-C$0.07N/A∞N/AN/A-973.97%-93.22%N/ALatest BUX, CRL, EDT, and AKU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025CRLCharles River Laboratories International$2.06$2.34+$0.28$0.50$942.34 million$984.17 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKUAkuminN/AN/AN/AN/AN/ABUXBiomark DiagnosticsN/AN/AN/AN/AN/ACRLCharles River Laboratories InternationalN/AN/AN/AN/AN/AEDTSpectral MedicalN/A1.45%N/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKUAkumin17.020.990.99BUXBiomark DiagnosticsN/AN/AN/ACRLCharles River Laboratories International0.651.411.14EDTSpectral Medical26.030.610.45Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKUAkumin36.10%BUXBiomark DiagnosticsN/ACRLCharles River Laboratories International98.91%EDTSpectral Medical12.99%Insider OwnershipCompanyInsider OwnershipAKUAkumin20.51%BUXBiomark DiagnosticsN/ACRLCharles River Laboratories International1.30%EDTSpectral Medical18.18%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKUAkumin3,63191.17 million72.47 millionNot OptionableBUXBiomark DiagnosticsN/AN/AN/ANot OptionableCRLCharles River Laboratories International21,40049.12 million50.47 millionOptionableEDTSpectral Medical29281.25 millionN/ANot OptionableBUX, CRL, EDT, and AKU HeadlinesRecent News About These CompaniesSpectral Medical (TSE:EDT) Shares Cross Above 50-Day Moving Average - Here's What HappenedJune 13, 2025 | marketbeat.comSpectral Medical (TSE:EDT) Reaches New 52-Week High - Still a Buy?June 11, 2025 | marketbeat.comSpectral Medical (TSE:EDT) Share Price Passes Above 50-Day Moving Average - What's Next?June 5, 2025 | marketbeat.comSpectral Medical (TSE:EDT) Reaches New 52-Week High - Here's WhyMay 29, 2025 | marketbeat.comSpectral Medical is “fundamentally undervalued”, Paradigm saysMay 9, 2025 | cantechletter.comSpectral Medical Inc.: Spectral Medical Announces First Quarter and Provides Corporate UpdateMay 9, 2025 | finanznachrichten.deSpectral Medical Inc.: Spectral Medical Announces Non-Dilutive Financing of Up to $10 Million with VantiveMay 7, 2025 | finanznachrichten.deSpectral Medical Full Year 2024 Earnings: Beats ExpectationsMarch 29, 2025 | finance.yahoo.comStocks in play: Spectral Medical Inc.March 27, 2025 | ca.finance.yahoo.comSpectral Medical Advances Amid Tigris Trial ChallengesDecember 3, 2024 | markets.businessinsider.comThe top TSX healthcare stocks under $1November 5, 2024 | msn.comSpectral Medical Nears Completion of Tigris TrialNovember 4, 2024 | markets.businessinsider.comSpectral announces last patient out in U.S. burn pivotal study at Burns CenterOctober 30, 2024 | markets.businessinsider.comSpectral AI Names Company Founder As Its New Board ChairmanOctober 19, 2024 | dallasinnovates.comSpectral Medical Provides September Tigris Trial UpdateOctober 3, 2024 | finance.yahoo.com12 Horrifyingly Haunted Hotels You Can Actually Stay at—If You DareSeptember 29, 2024 | currently.att.yahoo.comHow To Avoid Being Duped By Medical DisinformationSeptember 25, 2024 | forbes.comOPINION: We don't need a new prison in Letcher County, Kentucky, or anywhere elseSeptember 24, 2024 | news.yahoo.com'The Substance' review: Demi Moore dazzles in a derivative midnight snoozeSeptember 20, 2024 | yahoo.comSpectral AI Outlines U.S. Regulatory Pathway for DeepView® System for Burn IndicationSeptember 17, 2024 | tmcnet.comPaul M. Walker Sells 150,000 Shares of Spectral Medical Inc. (TSE:EDT) StockSeptember 17, 2024 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsStarbucks Stock: Culture Fix May Be Key to Long-Term GrowthBy Chris Markoch | June 12, 2025View Starbucks Stock: Culture Fix May Be Key to Long-Term GrowthBUX, CRL, EDT, and AKU Company DescriptionsAkumin NASDAQ:AKUAkumin Inc. provides outpatient diagnostic imaging services in the United States. It operates in two segments, Radiology and Oncology. The company offers various medical imaging services, including magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other diagnostic and interventional radiology procedures through owned and/or operated imaging locations. It provides outpatient radiology, and oncology services and solutions to hospitals and health systems across 48 states. Akumin Inc. was founded in 2015 and is headquartered in Plantation, Florida.Biomark Diagnostics CNSX:BUXBioMark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment. It has a collaborative research agreement with the Icahn School of Medicine for clinical studies related to early lung cancer diagnosis. The company was incorporated in 2014 and is headquartered in Richmond, Canada. BioMark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc.Charles River Laboratories International NYSE:CRL$151.16 +1.72 (+1.15%) Closing price 06/16/2025 03:59 PM EasternExtended Trading$151.79 +0.62 (+0.41%) As of 06/16/2025 07:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.Spectral Medical TSE:EDTC$0.87 -0.01 (-1.14%) As of 06/16/2025 02:54 PM EasternSpectral Medical Inc is focused on the development and commercialization of a treatment for septic shock utilizing its endotoxin activity assay (EAA) diagnostic and the toraymyxin therapeutic. The company also manufactures and sells proprietary reagents. The product line of the company consists of proprietary biochemical, EAA, and instrumentation. The segments of the group are Spectral Medical Inc, which is the key revenue-generating segment that manufactures and sells its EAA diagnostic and certain proprietary reagents; Dialco Medical Inc segment; and Corporate. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New Catalysts to Drive NVIDIA’s Stock Price Even Higher Palantir Defies Bears, Leads S&P 500 in 2025 AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap! Could Meta and Eli Lilly Trigger the Next Stock Split Boom? Iran Conflict Fuels Fertilizer Stocks’ Bullish Setup Is D-Wave's Latest $400M Sales Agreement a Dilution Deal-Breaker? Why Analysts Are Bullish on Celsius Stock After 30% Drop 3 Stocks With Rising Dividends Investors Shouldn’t Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
